The Biotech Talent Market Lessons of H1 2026 After two years of turbulence, the biotech talent market entered 2026 with cautious optimism — and the first half delivered some hard-won lessons. Here’s what the data
The impact of the current Trump-era trade policies and proposed pharmaceutical tariffs on pharma growth is likely to be mixed — creating both short-term disruption and some long-term domestic investment opportunities. Here’s what could happen
“After several years of headwinds, the backdrop for pharma and biotech has turned more constructive, supported by improved policy visibility, renewed M&A activity, and strong market performance.” — Janus Henderson, March 2026 2026 is shaping up
AI is transforming pharmaceutical commercial analytics, reshaping how companies engage with healthcare providers, patients, and payers while driving more data-driven, personalized, and efficient operations. Data-Driven Decision Making Traditionally, pharmaceutical commercial strategies relied on historical sales data
“Basel is really the emerging center of life science innovation outside of the United States. I can’t imagine starting a company without having a Basel site and a Boston site, and allowing those to work
The 2025 US pharma manufacturing landscape is characterized by significant investments, evolving regulatory frameworks, and a growing focus on AI-driven innovation. While the US remains the world’s largest pharmaceutical market, it’s also heavily reliant on global supply
